Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kate Rawson

Kate Rawson is a Contributing Editor at Prevision Policy. She was a Senior Editor at The RPM Report and reporter and editor at The Pink Sheet where she covered drug regulation and reimbursement issues. During her ten-year tenure at FDC Reports, she helped launch The Pink Sheet DAILY, and also served as Managing Editor of The Rose Sheet, which covers regulatory and business news of the cosmetics industry.
Set Alert for Articles By Kate Rawson

Latest From Kate Rawson

Oncology Pilot To Highlight Disagreements Between US FDA And Sponsor For Advisory Committees

'Point/Counterpoint' program grew out of Assessment Aid initiative in the Oncology Center of Excellence and will be unveiled at an upcoming ODAC meeting.

Cancer Advisory Committees

US FDA Oncology Leadership Shuffle Moves Patricia Keegan To OCE; Gootenberg Takes On Recruitment

US FDA's reorganization of drug reviews splits Keegan's old OHOP division into two.

Cancer Drug Review

OND Reorg Getting Warm Welcome From Review Divisions

Division directors are embracing the reorganization of US FDA's drug review operations.

Drug Review Leadership

US FDA Expands 'Cures' Hiring Authority To Fill Variety Of Open Positions

Originally used for leadership positions, the alternative pay scale and a revamped hiring pilot are now shortening the time for FDA to onboard even technical staff, but the Office of New Drugs remains 'very understaffed.'

FDA Leadership

US FDA 'Uni-Review' Rolls Out: Psychiatric Division Is Among Early Adopters

Shared review memorandum under Office of New Drugs reorg will help eliminate last-minute surprises between disciplines and provide greater consistency between divisions.

Neurology Drug Review

'Project Orbis' Oncology Pilot Eventually Will Target 'Major Impact' Applications

But US FDA is starting small, OCE Director Pazdur says. Program will hand-select approve high-priority oncology treatments that have to potential to change the standard of care.

Cancer Drug Review
See All
UsernamePublicRestriction

Register